ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) and NeuroSense Therapeutics (NASDAQ:NRSN – Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.
Profitability
This table compares ACADIA Pharmaceuticals and NeuroSense Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ACADIA Pharmaceuticals | -8.44% | -15.67% | -9.15% |
| NeuroSense Therapeutics | N/A | -678.59% | -207.30% |
Earnings & Valuation
This table compares ACADIA Pharmaceuticals and NeuroSense Therapeutics’ gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ACADIA Pharmaceuticals | $726.44 million | 3.85 | -$61.29 million | ($0.38) | -44.71 |
| NeuroSense Therapeutics | N/A | N/A | -$11.28 million | ($0.83) | -1.63 |
Risk and Volatility
ACADIA Pharmaceuticals has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500. Comparatively, NeuroSense Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and price targets for ACADIA Pharmaceuticals and NeuroSense Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ACADIA Pharmaceuticals | 0 | 3 | 12 | 0 | 2.80 |
| NeuroSense Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
ACADIA Pharmaceuticals presently has a consensus price target of $35.82, indicating a potential upside of 110.85%. Given ACADIA Pharmaceuticals’ higher possible upside, research analysts clearly believe ACADIA Pharmaceuticals is more favorable than NeuroSense Therapeutics.
Institutional & Insider Ownership
96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are owned by institutional investors. 27.5% of ACADIA Pharmaceuticals shares are owned by company insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
ACADIA Pharmaceuticals beats NeuroSense Therapeutics on 8 of the 13 factors compared between the two stocks.
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
About NeuroSense Therapeutics
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
